Characterization of the expression and immunological impact of the transcriptional activator CREB in renal cell carcinoma

[1]  B. Seliger,et al.  CREB1 is affected by the microRNAs miR-22-3p, miR-26a-5p, miR-27a-3p, and miR-221-3p and correlates with adverse clinicopathological features in renal cell carcinoma , 2020, Scientific Reports.

[2]  R. Flippot,et al.  Tyrosine kinase inhibitors and immunotherapy combinations in renal cell carcinoma , 2020, Therapeutic advances in medical oncology.

[3]  B. Seliger,et al.  Tumor-induced escape mechanisms and their association with resistance to checkpoint inhibitor therapy , 2019, Cancer Immunology, Immunotherapy.

[4]  M. Hurwitz,et al.  Current Status and Future Directions of Immunotherapy in Renal Cell Carcinoma , 2019, Current Oncology Reports.

[5]  Anas M. Saad,et al.  Trends in Renal‐Cell Carcinoma Incidence and Mortality in the United States in the Last 2 Decades: A SEER‐Based Study , 2019, Clinical genitourinary cancer.

[6]  M. Quintanilla,et al.  New Insights Into the Role of Qa-2 and HLA-G Non-classical MHC-I Complexes in Malignancy , 2018, Front. Immunol..

[7]  A. Lin,et al.  Heterogeneity of HLA-G Expression in Cancers: Facing the Challenges , 2018, Front. Immunol..

[8]  E. Lam,et al.  Renal cell carcinoma: a review of biology and pathophysiology , 2018, F1000Research.

[9]  ping wang,et al.  Cyclic AMP responsive element-binding protein induces metastatic renal cell carcinoma by mediating the expression of matrix metallopeptidase-2/9 and proteins associated with epithelial-mesenchymal transition. , 2017, Molecular medicine reports.

[10]  Charles Swanton,et al.  Renal cell carcinoma , 2017, Nature Reviews Disease Primers.

[11]  S. Quezada,et al.  A CCR4 antagonist reverses the tumor-promoting microenvironment of renal cancer , 2017, The Journal of clinical investigation.

[12]  S. George,et al.  VEGF inhibitors in renal cell carcinoma. , 2016, Clinical advances in hematology & oncology : H&O.

[13]  D. Qian,et al.  Systemic Inhibition of CREB is Well-tolerated in vivo , 2016, Scientific Reports.

[14]  B. Seliger,et al.  HLA-E expression and its clinical relevance in human renal cell carcinoma , 2016, Oncotarget.

[15]  P. Humphrey,et al.  The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours. , 2016, European urology.

[16]  F. Marincola,et al.  Identification of novel microRNAs regulating HLA-G expression and investigating their clinical relevance in renal cell carcinoma , 2016, Oncotarget.

[17]  M. Terris,et al.  Renal cell carcinoma: links and risks , 2016, International journal of nephrology and renovascular disease.

[18]  ping wang,et al.  Cyclic AMP responsive element-binding protein promotes renal cell carcinoma proliferation probably via the expression of spindle and kinetochore-associated protein 2 , 2016, Oncotarget.

[19]  E. Carosella,et al.  A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G. , 2015, European urology.

[20]  B. Seliger,et al.  Clinical relevance of miR-mediated HLA-G regulation and the associated immune cell infiltration in renal cell carcinoma , 2015, Oncoimmunology.

[21]  V. Pistoia,et al.  Interactions between HLA-G and HLA-E in Physiological and Pathological Conditions , 2014, Front. Immunol..

[22]  B. Seliger,et al.  The role of classical and non-classical HLA class I antigens in human tumors. , 2012, Seminars in cancer biology.

[23]  Wong-Ho Chow,et al.  Epidemiology and risk factors for kidney cancer , 2010, Nature Reviews Urology.

[24]  B. Seliger,et al.  Expression and regulation of non-classical HLA-G in renal cell carcinoma. , 2008, Tissue antigens.

[25]  W. Leonard,et al.  CREB/ATF-dependent T cell receptor–induced FoxP3 gene expression: a role for DNA methylation , 2007, The Journal of experimental medicine.

[26]  B. Seliger,et al.  Functional role of human leukocyte antigen-G up-regulation in renal cell carcinoma. , 2003, Cancer research.

[27]  A. Rudensky,et al.  Foxp3 programs the development and function of CD4+CD25+ regulatory T cells , 2003, Nature Immunology.

[28]  P. J. van den Elsen,et al.  HLA-G Transactivation by cAMP-response Element-binding Protein (CREB) , 2002, The Journal of Biological Chemistry.

[29]  N. Rouas-Freiss,et al.  HLA-G: An Immune Checkpoint Molecule. , 2015, Advances in immunology.